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Case repOrt
A 62-year-old Filipino man with a history of chronic obstructive 
pulmonary disease, hypertension, and hyperlipidemia was 
admitted to the emergency department at Hospital A with 
recurrent fevers, weakness, and jaundice. The patient was 
evaluated and eventually discharged with a diagnosis of 
possible drug-induced hepatitis. One month later, the patient 
was admitted to Hospital B for recurrent fevers and weakness. 
The patient’s hemoglobin was 3.8 g/dL. Six units of packed red 
blood cells (RBCs) were ordered for transfusion. The patient’s 
sample typed as group B, D+, and the antibody screen was 
negative. All six units of packed RBCs appeared compatible 
(at immediate spin) and were transfused to the patient. His 
hemoglobin level 4 days post-transfusion was 9.3 g/dL, and the 
patient was discharged. The patient returned after a week for 
follow-up and his hemoglobin was found to have dropped to 8.5 
g/dL, which continued to fall until it reached 7.0 g/dL. Additional 
packed RBCs were ordered for transfusion. During subsequent 
pre-transfusion compatibility testing, the antibody screen was 
found to be positive (all screening cells reactive at the antihuman 
globulin phase). An antibody identification panel was performed. 
The patient’s serum was found to react with all panel cells tested, 
including the autocontrol tube. A direct antiglobulin test revealed 
the presence of both anti-IgG and anti-C3 coating the patient’s 
RBCs. The specimen was then sent to a reference laboratory for 
further testing. Results from the reference lab testing revealed the 
presence of anti-Jk3 in the patient’s serum. The patient was placed 
on steroids, and his reticulocyte count increased with no further 
signs of extravascular hemolysis. No additional transfusions were 
necessary. He was eventually discharged with a hemoglobin of 
13.6 g/dL. The purpose of this case study is to report the findings 
of an extremely rare but clinically significant antibody, anti-Jk3. 
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The Kidd blood group system is defined by two antigens, 
Jka and Jkb, that yield four different phenotypes: Jk(a+b+), 
Jk(a+b–), Jk(a–b+), and Jk(a–b–). Jk(a–b–) is also known 
as Jk:–3 or the Jknull phenotype. The antigens Jka and Jkb 
were discovered by Allen, Diamond, and Niedziela in 19511 
and the Jk(a–b–) phenotype was discovered soon after 
by Pinkerton and Mermod in 1959.2 Individuals with the 
Jk(a–b–) phenotype lack both Jka and Jkb. The Jk(a–b–) 
phenotype can result from the homozygous inheritance of 
recessive alleles that produce neither Jka nor Jkb or from the 
inheritance of a dominant inhibitor gene, In(Jk), reported to 
have no association with the Jk locus but causes a suppression 
of the expression of Kidd antigens.3 The Jk(a–b–) phenotype 
is seen more frequently in people of Polynesian, Filipino, and 
Chinese descent.4
The first reported occurrence of the Jk(a–b–) phenotype 
was detected in a Filipino woman with Chinese and Spanish 
ancestry.5 The Jk(a–b–) phenotype is rare among white and 
black populations and is more common among Polynesians, 
Filipinos, and Chinese.3,6 The Jk(a–b–) phenotype frequency 
among the white population is less than 0.1 percent.6 In Taiwan, 
the Jk(a–b–) phenotype was found to be 1.0 percent among 
the Rukai tribe and 1.2 percent among the Paiwan tribe.7 
Among Polynesians, the Jk(a–b–) phenotype frequency is 1.4 
percent.6 The Jk(a–b–) phenotype has also been reported to 
occur more frequently in Indian, Brazilian, Japanese, and Thai 
populations.8
Alloantibodies to Kidd antigens are clinically significant 
in transfusion recipients and women who are pregnant. The 
antibodies are produced in reaction to antigen exposure 
during a previous transfusion or pregnancy and remain in 
low titer in plasma until secondary exposure occurs. Kidd 
antibodies are capable of binding complement and are known 
to cause both immediate and delayed hemolytic transfusion 
reactions (DHTRs) as well as hemolytic disease of the fetus 
and newborn (HDFN). The production of anti-Jk3 occurs only 
in individuals who have inherited recessive alleles causing the 
Jk(a–b–) phenotype; those who have inherited the dominant 
inhibitor gene In(Jk) cannot make anti-Jk3.8 Anti-Jk3 is best 
detected by the indirect antiglobulin test (IAT) and can be 
enhanced with enzyme pretreatment of RBCs used in antibody 
identification procedures.
Case Report
A 62-year-old Filipino man with a history of chronic 
obstructive pulmonary disease, hypertension, and 
hyperlipidemia was admitted to the emergency department 
at Hospital A with recurrent fevers, weakness, and 
jaundice. His liver function tests were elevated: aspartate 
aminotransferase (AST) = 64 IU/L (normal 1–40 IU/L), 
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alanine aminotransferase (ALT) = 85 IU/L (normal range 
7–567 IU/L), alkaline phosphatase (ALP) = 561 IU/L (normal 
range 44–147 IU/L), total bilirubin = 1.8 mg/dL (normal 
range 0.3–1.9 mg/dL), and an ultrasound showed some 
evidence of liver disease of uncertain cause. He underwent 
magnetic resonance cholangiopancreatography (MRCP), 
which showed no evidence of biliary obstruction/dilation or 
stones. Other serologic testing for infectious disease markers 
and autoimmune disorders was negative. 
His hemoglobin was low, between 7 and 9 g/dL (normal 
range elderly male: 12.4–14.9 g/dL), and serum ferritin was 
greater than 2,000 (normal range male: 12–300 ng/mL). 
The patient’s peripheral blood smear was unremarkable with 
the exception of leukocytosis and the presence of target cells. 
Target cells were suggestive of biliary obstruction/dilation 
or stones, but this was ruled out by MRCP. The patient also 
had a high serum ferritin level, which is a common finding 
in patients with liver disease. In a patient experiencing a 
DHTR, schistocytes and reticulocytosis may be present on the 
peripheral blood smear; they were absent in this patient. The 
bone marrow biopsy did show hypocellularity with atypical 
megakaryocytic hyperplasia and erythroblastopenia. An 
IgG plasma cell dyscrasia was also noted with 13 percent to 
15 percent plasma cells (flow and immunofixation positive, 
fluorescence in situ hybridization [FISH] negative) with serum 
protein electrophoresis of 1.5 (reference range: 0.7–1.5 g/dL). 
Results of genetic testing revealed the patient to be JAK2-
negative and FISH for BCR/ABL–negative, but positive for 
three copies of ABL1 w/trisomy 9/9q, which can be associated 
with BCR/ABL1-negative chronic myeloproliferative disease, 
myelodysplastic syndrome, acute myelogenous leukemia, 
and, rarely, B-cell acute lymphoblastic leukemia. Tests for 
parvovirus B19 (serum IgM and immunohistochemistry) on 
the bone marrow were negative, but the presence of intra-
nuclear eosinophilic inclusions in the bone marrow suggested 
possible parvovirus infection.
The patient was subsequently discharged. The patient was 
admitted to Hospital B 1 month later with recurrent fevers and 
weakness. His hemoglobin was 3.8 g/dL. A peripheral blood 
smear showed signs of leukocytosis (29K) (normal range male: 
4.5–11.0K) and thrombocytosis (normal range: 150–450K). 
A bone marrow biopsy showed hypercellularity with atypical 
megakaryocytes, hyperplasia, and erythroblastopenia. 
IgG plasma cell dyscrasia was noted with 13 percent to 
15 percent plasma cells and the presence of eosinophilic 
inclusions suggestive of parvovirus infection. Serologic tests 
for parvovirus were negative. A type and crossmatch for six 
units of blood was ordered. The patient was found to be group 
B, D+–; the antibody screen was negative; and all six units 
ordered appeared compatible (immediate spin crossmatch). 
The patient received all six units of type-specific, packed red 
blood cells (RBCs) with no signs of adverse reaction. The 
patient was also given intravenous immunoglobulin (IVIG) 
for the suspected parvovirus infection. His hemoglobin level 4 
days post-transfusion was 9.3 g/dL, and he was discharged 10 
days from date of admittance. 
The patient returned to Hospital B 1 week later for follow-
up with an oncologist, and his hemoglobin was found to have 
dropped to 8.5 g/dL, which continued to fall until it reached 
7.0 g/dL (approximately 19 days after transfusion). Additional 
packed RBCs were ordered for transfusion. During subsequent 
compatibility testing procedures, the antibody screen was 
found to be positive with all screening cells at the antihuman 
globulin (AHG) phase of testing. An antibody identification 
panel was performed. The patient’s serum was found to 
react with all panel cells tested including the autocontrol 
tube at the AHG phase of testing. A direct antiglobulin test 
(DAT) panel was performed using polyspecific (anti-IgG + 
anti-C3) and monospecific AHG reagents (anti-IgG, anti-C3). 
The results of the DATs showed both anti-IgG and anti-C3 
coating the patient’s RBCs. The specimen was then sent to 
a reference laboratory for further testing. Results from the 
reference lab testing using a polyethylene glycol (PEG)-IAT 
method revealed the presence of anti-Jk3 in the patient’s 
serum. An elution was not performed because the patient had 
not been transfused within the previous 2 weeks. Aliquots 
of the patient’s serum were adsorbed using allogeneic cells. 
Clinically significant antibodies to other major blood group 
antigens were excluded by the PEG-IAT using the adsorbed 
plasma. Phenotyping was performed on autologous neocytes 
recovered by microhematocrit centrifugation. Results of the 
phenotyping showed the patient to be Jk(a–b–). Genomic 
sequencing was also performed on the patient’s RBCs to 
determine the genotype that would allow for the prediction of 
the patient’s phenotype. Results of the genetic testing revealed 
the presence of two variant alleles that were detected by JK-
cDNA analysis and genomic sequencing. Jk*02N.01 carried 
the intron 5c.342-1g>a variant that is associated with exon 6 
skipping and a null Jk(b–) phenotype. The Jk*01 allele carried 
the two known changes of c.130G>A and c.893G>A, not 
normally reported on the same allele. The JKc.130A single-
nucleotide polymorphism (SNP) is associated with weakened 
antigen expression, and the c.893A SNP is associated with a 
null Jk(a–) phenotype. It was recommended, if transfusion 
was necessary, to select ABO/Rh compatible units negative for 
both Jka and Jkb.
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Discussion
This case report focuses on a clinically significant 
but infrequent antibody known as anti-Jk3. The clinical 
significance of anti-Jk3 is that it displays weak reactivity in 
vitro but has the capacity to induce severe RBC destruction in 
vivo in the presence of Jka and/or Jkb.3 Anti-Jk3 will present 
as a “panagglutinin” because the antibody will react with all 
panel cells, since all panel cells are Jk(a+b–), Jk(a–b+), or 
Jk(a+b+).9,10 The autocontrol tube may be either positive or 
negative depending on whether or not the patient has been 
recently transfused. The DAT will usually be positive for 
both anti-IgG and anti-C3. If the patient has been recently 
transfused (within the last 3 months), the use of allogeneic cells 
for adsorption procedures is necessary to rule out antibodies 
to other major blood group antigens. The decision to perform 
an elution rests with a facility’s protocol(s). Some facilities may 
elect to do an elution on any patient specimen with positive 
DAT results, whereas other facilities may be more selective 
in terms of number of days following a recent transfusion. 
The patient was questioned concerning transfusion of blood 
at other facilities and reported that he had never received a 
transfusion prior to the units that were given at Hospital B. 
The timing of this DHTR is consistent with the formation of a 
new antibody rather than an evanescent form. 
Another laboratory test that can be helpful in the 
identification of the Jk(a–b–) phenotype is the urea lysis test. 
In 1982, Heaton and McLoughlin showed that Jk(a–b–) RBCs 
were resistant to lysis in the presence of 2M urea. RBCs with 
normal Kidd phenotypes rapidly swell and will lyse in the 
presence of 2M urea.11 In 1995, another group showed that the 
Kidd blood group antigens and urea transport function were 
carried on the same protein structure. As a result, individuals 
with the Jk(a–b–) phenotype may not be able to concentrate 
urine as well as individuals with normal Kidd antigens.12
Serologic phenotyping is most commonly used to identify 
specific antigens on RBCs. A patient with the Jk(a–b–) 
phenotype should be nonreactive when tested with anti-Jka 
and anti-Jkb typing sera. It is important to check the patient’s 
transfusion history, since recent transfusion could invalidate 
phenotyping results. If the patient has been recently trans-
fused, autologous neocytes prepared through microhematocrit 
centrifugation can be used for phenotyping. Genotyping for 
Kidd variants may also be used to support serologic typing and 
to predict Kidd phenotypes when antisera are unavailable.13 
This particular patient was shown to have inherited two 
variant alleles producing the Jk(a–b–) phenotype. Jk(a–b–) 
RBCs are recommended for transfusion in patients with anti-
Jk3. Because of the rareness of the Jk(a–b–) phenotype, it is 
difficult to find blood for these patients. Finding compatible 
units for such patients will require the use of rare donor 
registries. Siblings of the patient can also be tested to see if 
they might be of the same phenotype as the patient.
In this case, IVIG was given to the patient because of the 
suspected parvovirus infection. This is one of the off-label 
uses of IVIG as described by Hillyer et al.14 Also, because 
IVIG is prepared from pools of donor plasma, it may contain 
antibodies to blood group antigens (e.g., anti-A, -B, -D, and 
-K; panagglutinins). In this particular case, the IVIG did not 
interfere in the serologic testing used to identify the antibody 
present in the patient’s serum.
Conclusion
This case report presents the findings of an extremely 
rare but clinically significant antibody. Anti-Jk3 is capable of 
causing severe DHTRs and HDFN. This antibody is difficult 
to identify in that it will present as a “panagglutinin,” meaning 
that it will react with all panel cells tested, since they are 
typically either Jk(a+) or Jk(b+) or both. The autocontrol 
may be positive if the patient has been recently transfused. 
If the autocontrol is positive, a DAT should be performed to 
characterize the protein coating the patient’s RBCs. An elution 
should also be performed to identify the antibody coating the 
patient’s RBCs, since it is not safe to assume that the antibody 
present in the patient’s serum is the same antibody that is 
coating the patient’s RBCs. Because most blood banks and 
transfusion services have limited resources, confirmation 
of the antibody specificity and phenotyping of the patient’s 
RBCs may need to be performed by a reference laboratory. 
Only blood that is Jk(a–b–) should be transfused to patients 
with anti-Jk3. Because of the difficulty in finding compatible 
units for such patients, rare donor registries will need to be 
consulted in the event that transfusion is required. The use of 
IVIG for patient treatment must be taken into consideration 
when performing serologic workup for suspected transfusion 
reactions because of contaminating antibodies that may be 
present in the formulation that could interfere with serologic 
testing.
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